Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 67Polycystic Ovary Syndrome 3Neoplasms, Hormone-Dependent 3Neoplasm Metastasis 2Carcinoma, Lobular 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Ductal, Breast 2Breast Diseases 2Breast Cancer Female 2Advanced Breast Cancer 2Sexuality 1Sexual Dysfunctions, Psychological 1Osteoporosis 1Luminal B/HER2-negative Breast Cancer 1Leiomyoma 1Infertility 1Hot Flashes 1Hormone Receptor Positive Breast Carcinoma 1Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1HR+/HER2- Early Breast Cancer 1HR+/HER2+ Early Breast Cancer 1Fractures, Bone 1Estrogen Receptor and/or Progesterone Receptor Positive 1Endometrial Stromal Tumors 1Endometrial Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms, Male 1Breast Carcinoma In Situ 1Breast Cancer Metastatic 1Bone Diseases, Metabolic 1

Interventions

Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Luminal B/HER2-negative Breast Cancer × Aromatase Inhibitors × Clear all
NCT05640778 2024-01-31

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown
30 enrolled
Breast

Luminal B/HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡